Home / Health / Gene Therapy Halves Cholesterol for a Year
Gene Therapy Halves Cholesterol for a Year
28 Aug
Summary
- One-time gene therapy significantly reduced LDL cholesterol levels.
- Highest dose treatment kept cholesterol levels steady for a year.
- This one-and-done treatment shows long-term potential for common diseases.
A novel, one-time gene-editing treatment has demonstrated sustained success in reducing LDL cholesterol levels a year after administration. In a recent small-scale safety study involving 15 patients, those who received the highest dosage experienced a significant 50% drop in their cholesterol and triglyceride levels, with these effects persisting throughout the year.
This pioneering approach, which targets the ANGPTL3 gene in the liver, offers a potential "one-and-done" alternative to lifelong chronic treatments for conditions like high cholesterol. While early safety studies are ongoing and the therapy is years away from widespread clinical use, the accumulating evidence indicates its viability and durability. Future trials are planned to further assess safety and efficacy, with potential availability projected for the early 2030s.
